Everspin Q3 revenue beats guidance; Q4 outlook strong

What happened

Everspin reported Q3 revenue of $20.6 million, a 47% increase year-over-year and slightly above its guidance range. The growth was driven by both product sales and non-product revenue, suggesting broad-based strength. Management guided to Q4 revenue of $21.5-22.5 million, indicating sequential growth is expected to continue. However, the press release does not provide a breakdown of how much came from the Amentum defense subcontract or higher-density xSPI MRAM shipments, which were key catalysts identified in our prior report. Until the 10-Q is filed, the evidence of defense milestone accounting and xSPI mix shift remains incomplete, so the fundamental picture is not yet fully validated.

Implication

The strong revenue and guidance reinforce that demand is improving, reducing the probability of the bear case where channel digestion and weak demand would pressure shares. However, the valuation remains elevated at EV/EBITDA over 200x and P/E over 2000x, so the stock still needs clear evidence of sustainable growth to justify the price. We maintain our WAIT rating but note that the risk-reward has modestly improved; our base case implied value of $27 is now more attainable if defense and xSPI contributions materialize as expected. Key items to monitor in the forthcoming 10-Q include contract assets/liabilities from the Amentum subcontract, over-time revenue recognition, and any commentary on xSPI shipment mix. Until those details confirm the source of growth, we do not recommend adding to positions above $32, and would look to accumulate near $18 if the stock retraces.

Thesis delta

The Q3 revenue beat and strong Q4 guidance indicate that the company's growth trajectory is on track, but we still lack confirmation that the growth is from the high-conviction defense and xSPI catalysts. As a result, our WAIT rating remains unchanged, though the probability of the bull case has marginally increased from 20% to around 25%, while the bear case probability has decreased from 35% to 30%. The next catalyst is the 10-Q filing, which will either validate the thesis shift or show that the revenue beat is from lower-quality sources.